Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC. we chose an antibody that does not compete with trastuzumab or pertuzumab for binding. conjugated to a reduced potency PBD (pyrrolobenzodiazepine) dimer payload. https://leoners.shop/product-category/coffee-table-set/